MODIFICATIONS OF ERYTHROPOIESIS IN MYELODYSPLASTIC SYNDROMES TREATED WITH RECOMBINANT ERYTHROPOIETIN AS EVALUATED BY SOLUBLE TRANSFERRIN RECEPTOR, HIGH FLUORESCENCE RETICULOCYTES AND HYPOCHROMIC ERYTHROCYTES
P. Musto et al., MODIFICATIONS OF ERYTHROPOIESIS IN MYELODYSPLASTIC SYNDROMES TREATED WITH RECOMBINANT ERYTHROPOIETIN AS EVALUATED BY SOLUBLE TRANSFERRIN RECEPTOR, HIGH FLUORESCENCE RETICULOCYTES AND HYPOCHROMIC ERYTHROCYTES, Haematologica, 79(6), 1994, pp. 493-499
Background. The aim of this study was to evaluate changes in erythropo
iesis induced in vivo by recombinant erythropoietin (r-EPO) treatment
in myelodysplastic syndromes (MDS), by means of some new, non invasive
laboratory parameters. Patients and Methods. Serum levels of soluble
transferrin receptor (STR), a marker of total marrow erythroid activit
y, and automated detection of high fluorescence reticulocytes (HFR) an
d hypochromic erythrocytes (HE) (respectively, indexes of effective er
ythropoiesis and functional iron deficiency) were longitudinally measu
red in 25 MDS patients treated with r-EPO, and then correlated with co
nventional clinical and laboratory features. Results. Stimulation of e
rythropoiesis was documented in 8 patients, whose serum STR levels sho
wed a significant, early (within 16 days) increase during treatment wi
th r-EPO. However, only 3 of these patients demonstrated a concomitant
rise in HFR, and these were the only subjects who experienced a signi
ficant clinical response. Two of these patients also developed a funct
ional iron deficiency while on treatment, as documented by an increase
in HE, despite normal serum iron, transferrin saturation and even ver
y high levels of ferritin. They needed iron supplementation to maintai
n the response to r-EPO. No variation in STR, HFR or HE occurred in th
e remaining 17 unresponsive patients during at least two months of tre
atment. Serum levels of thymidine kinase, an aspecific marker of cellu
lar proliferative activity, paralleled those of STR. No correlation wa
s found between STR, HFR or HE and serum level of endogenous EPO, hemo
globin or transfusion requirements in MDS patients. Conclusions. These
findings suggest that there is a heterogeneous and complex pattern of
erythroid response in MDS patients treated with r-EPO. In addition, o
ur results indicate that STR, HFR and HE may provide useful informatio
n for the clinical management of these patients.